On-Demand and Intermittent Therapy for Gastro-Oesophageal Reflux Disease
- 1 January 2002
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 20 (9) , 565-576
- https://doi.org/10.2165/00019053-200220090-00001
Abstract
Since gastro-oesophageal reflux disease (GORD) is a prevalent condition characterised by frequent relapses, long-term costs of management for this disease are high. Thus, strategies to decrease resource expenditures without impairing patient quality of life are desirable. On-demand therapy (one-dose when symptoms occur) and intermittent therapy (short course of medication when symptoms occur) are attractive since pharmaceutical expenditures may be decreased, and many patients self-employ this strategy. The purpose of this paper was to examine the economic implications of on-demand or intermittent therapy for GORD. A review of selected studies evaluating medication suitable for on-demand or intermittent administration was performed. A complete search for published studies on the cost effectiveness of on-demand or intermittent therapy for GORD was conducted, and the results discussed in detail. Antacids, alginates, topically active agents, histamine(2)-receptor antagonists, and proton pump inhibitors have all demonstrable efficacy compared with placebo when administered on-demand. Proton pump inhibitors constitute the most effective pharmacological means to treat GORD. Although step-up strategies initially using less potent medication may decrease resource use, cost-effectiveness analysis illustrates that on-demand or intermittent therapy with proton pump inhibitors may be reasonable options. Further work that defines quality of life and patient preferences associated with GORD may allow for proper allocation of resources for the management of this condition.Keywords
This publication has 30 references indexed in Scilit:
- Onset of action during on‐demand treatment with Maalox suspension or low‐dose ranitidine for heartburnAlimentary Pharmacology & Therapeutics, 1999
- Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteersAlimentary Pharmacology & Therapeutics, 1999
- Economic analysis of step‐wise treatment of gastro‐oesophageal reflux diseaseAlimentary Pharmacology & Therapeutics, 1999
- Economic Evaluation of Long Term Management Strategies for Erosive OesophagitisPharmacoEconomics, 1999
- On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tabletsClinical Therapeutics, 1997
- Acute effects of antacids on gastric juice components in duodenal ulcer patientsEuropean Journal of Clinical Investigation, 1990
- Symptomatic Effect of a Low-Dose Antacid Regimen in Reflux OesophagitisScandinavian Journal of Gastroenterology, 1989
- Sucralfate versus Placebo in Reflux Esophagitis: A Double-Blind Multicenter StudyScandinavian Journal of Gastroenterology, 1988
- Ranitidine and High-Dose Antacid in Reflux OesophagitisScandinavian Journal of Gastroenterology, 1985
- A Multicentric, Randomized Clinical Trial of Gaviscon in Reflux EsophagitisSouthern Medical Journal, 1978